Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1 study found for:    7563203 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Withdrawn A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors
Conditions: Sarcoma;   Neuroblastoma;   Wilms Tumor;   Osteosarcoma;   Brain Tumor
Intervention: Drug: Pazopanib (GW786034)

Indicates status has not been verified in more than two years